

Claims

Sub
D
5

1. Pharmaceutical preparation containing as an active agent a pharmacologically acceptable salt of dichloromethylene bisphosphonic acid, characterized in that it is an oral solid dosage form comprising silicified microcrystalline cellulose.

2. Preparation according to claim 1, characterized in that it comprises 5-25 % by weight of silicified microcrystalline cellulose.

10
Sub
D

3. Preparation according to claim 1, characterized in that it comprises

a) from about 60 to 80 % by weight of anhydrous disodium clodronate;

b) from about 8 to 20 % by weight of silicified microcrystalline cellulose; and

c) from about 0.5 to 10 % by weight of lubricants and/or disintegrants.

15a

4. Preparation according to ^{claim 1} ~~any one of the preceding claims~~ wherein silicon dioxide is present in the silicified microcrystalline cellulose in an amount of from about 0.1 to 20 % by weight, based on the weight of the microcrystalline cellulose.

20a

5. Preparation according to ^{claim 1} ~~any one of the preceding claims~~, characterized in that it is a tablet or capsule.

25

6. Preparation according to ^{claim 1} ~~any one of the preceding claims~~, characterized in that the salt of dichloromethylene bisphosphonic acid is the disodium salt.

7. Process for the manufacture of a pharmaceutical preparation according to claim 1 characterized in that a wet granulation technique is used.

30

8. Process for the manufacture of a pharmaceutical preparation according to claim 1, characterized in that a dry granulation technique is used.

09465974-051900

424
400

451

Sub
D
25

9. Process for the manufacture of a pharmaceutical preparation according to claim 1, characterized in that a direct compression technique is used.

- 5 10. Use of silicified microcrystalline cellulose for the manufacture of a pharmaceutical preparation containing as an active agent a pharmacologically acceptable salt of dichloromethylene bisphosphoric acid.

add
B'

add
C'

00486971-054900